1 A unique cytotoxic CD4 <sup>+</sup> T cells signature defines critical COVI					
2	Sarah Baird <sup>1,2†</sup> , Caroline L. Ashley <sup>1,2†</sup> , Felix Marsh-Wakefield <sup>1,3</sup> , Sibel Alca <sup>1,2</sup> , Thomas M.				
3	Ashhurst <sup>1,4</sup> , Angela L. Ferguson <sup>1</sup> , Hannah Lukeman <sup>1,2</sup> , Claudio Counoupas <sup>1,5</sup> , Jeffrey J. Post <sup>6</sup> ,				
4	Pamela Konecny <sup>7</sup> , Adam Bartlett <sup>8,9,10</sup> , Marianne Martinello <sup>8</sup> , Rowena A. Bull <sup>8,9</sup> , Andrew Lloyd <sup>8</sup> ,				
5	Alice Grey <sup>11</sup> , Owen Hutchings <sup>11</sup> , Umaimainthan Palendira <sup>1</sup> , Warwick J. Britton <sup>5,12</sup> , Megan				
6	Steain <sup>1,2*</sup> & James A. Triccas <sup>1,2*</sup>				
7					
8	<sup>1</sup> School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney,				
9	Camperdown, NSW, Australia				
10	<sup>2</sup> Sydney Institute for Infectious Diseases and the Charles Perkins Centre, The University of Sydney,				
11	Camperdown, NSW, Australia				
12	<sup>3</sup> Vascular Immunology Unit, The University of Sydney, Sydney, New South Wales, Australia				
13	<sup>4</sup> Sydney Cytometry Core Research Facility, Charles Perkins Centre, Centenary Institute and The				
14	University of Sydney				
15	<sup>5</sup> Tuberculosis Research Program, Centenary Institute, Sydney, NSW, Australia				
16	<sup>6</sup> Prince of Wales Clinical School, UNSW Australia, Sydney, NSW Australia				
17	<sup>7</sup> St George Hospital, Sydney, New South Wales, Australia				
18	<sup>8</sup> The Kirby Institute, UNSW, Sydney, NSW, Australia				
19	<sup>9</sup> School of Biomedical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia				
20	<sup>10</sup> Sydney Children's Hospital, Sydney, NSW, Australia				
21	<sup>11</sup> RPA Virtual Hospital, Sydney Local Health District, Sydney, NSW, Australia.				
22	<sup>12</sup> Department of Clinical Immunology, Royal Prince Alfred Hospital, Camperdown, Australia				
23 24 25 26	*Address correspondence to James A. Triccas; <u>jamie.triccas@sydney.edu.au</u> or Megan Steain; <u>megan.steain@sydney.edu.au</u>				
27 28	<sup>†</sup> These authors contributed equally to this work				
30	Running title: Cytotoxic T cells and COVID-19 severity				
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. $\!1$				

#### 31 Abstract

32 Background and objectives. SARS-CoV-2 infection causes a spectrum of clinical disease 33 presentation, ranging from asymptomatic to fatal. While neutralising antibody (NAb) responses 34 correlate with protection against symptomatic and severe infection, the contribution of the T cell 35 response to the resolution or progression of disease is still unclear. Optimal protective immunity 36 may require activation of distinct immune pathways. As such, defining the contribution of 37 individual T cell subsets to disease outcome is imperative to inform the development of next-38 generation COVID-19 vaccines. To address this, we performed immunophenotyping of T cell 39 responses in unvaccinated individuals, representing the full spectrum of COVID-19 clinical 40 presentation. Methods. Spectral cytometry was performed on peripheral blood mononuclear cell 41 samples from patients with PCR-confirmed SARS-CoV-2 infection. Computational and manual 42 analyses were used to identify T cell populations associated with distinct disease states through 43 unbiased clustering, principal component analysis and discriminant analysis. Results. Critical 44 SARS-CoV-2 infection was characterised by an increase in activated and cytotoxic CD4<sup>+</sup> (CTL) 45 cells of a T follicular helper ( $T_{FH}$ ) or effector memory re-expressing CD45RA ( $T_{EMRA}$ ) phenotype. 46 These CD4<sup>+</sup> CTLs were largely absent in those with less severe disease. In contrast, those with 47 asymptomatic or mild disease were associated with high proportions of naïve T cells and reduced 48 expression of activation markers. Conclusion. Highly activated and cytotoxic CD4<sup>+</sup> T cell 49 responses may contribute to cell-mediated host tissue damage and progression of COVID-19. 50 Potential for induction of these detrimental T cell responses should be considered when developing 51 and implementing effective COVID-19 control strategies.

52

53 **Keywords.** SARS-CoV-2, COVID-19, T cells, Spectral Cytometry, CD4-CTLs.

#### 54 Introduction

55 The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been ongoing 56 since March of 2020. As of February 2023, over 754 million cases of SARS-CoV-2 infection and 6.83 million fatalities from coronavirus disease 2019 (COVID-19) have been reported.<sup>1</sup> While 57 58 several vaccines are now available for use, SARS-CoV-2 remains a leading cause of infectious 59 disease death globally. One of the major challenges with SARS-CoV-2 infection is the spectrum of 60 COVID-19 clinical presentation, ranging from asymptomatic to fatal. It is thought that more severe 61 disease results from a dysregulated immune response to infection; however, variability in this 62 immune dysfunction between individuals has limited understanding of the correlates of disease 63 severity. Developing a more comprehensive understanding of the immune response across the 64 spectrum of COVID-19 clinical presentation will help to differentiate protective from pathogenic 65 immune responses. This is essential to inform the development of next-generation therapies and 66 vaccines against SARS-CoV-2, with improved longevity and efficacy against newly emerging 67 variants of concern (VOC).

68 The key correlate of protective immunity against infection and severe disease in COVID-19 is neutralising antibody responses (NAb).<sup>2,3</sup>As such, the factors that contribute to breakthrough 69 70 infection following vaccination centre around humoral immune responses, such as waning NAb titres, and antibody escape mutations on globally dominant VOC.<sup>4-9</sup> The T cell response appears to 71 72 have greater longevity than detectable NAbs, with sustained response to antigen stimulation demonstrated >1-year post-infection.<sup>10,11</sup> Additionally, the dominant T cell epitopes do not overlap 73 74 with areas of high mutation on variant viruses, and as a result the T cell response is preserved against antibody-escape VOC. 9,12-16 Considering the limitations of current vaccines, it has been 75 76 suggested that the long-lived T cell response against SARS-CoV-2 variants may contribute to protective immunity in the absence of a robust humoral immune response.<sup>12,13,16</sup> While NAb 77 78 responses have been shown to tightly correlate with protection against disease, no such correlation

has been shown with the T cell response to SARS-CoV-2.<sup>17</sup> There is evidence that polyfunctional and cross-reactive T cell responses to seasonal coronaviruses are associated with milder disease and faster viral clearance.<sup>18–20</sup> However, several studies have also described an expansion of highly activated T cells in severe COVID-19, that could potentially contribute to excessive inflammatory immune responses and host-tissue damage.<sup>21–23</sup> As such, whether T cells play a protective or pathogenic role in COVID-19 is still unresolved.

85

To better define the role of T cell subsets, we performed an explorative investigation into T cell phenotypes across the clinical spectrum of COVID-19 presentation, utilising an unbiased analysis approach with a T-cell-centric high-dimensional cytometry panel. We report that critical COVID-19 infection is characterised by a shift from naïve T cell phenotypes to an expansion of cytotoxic CD4<sup>+</sup>T lymphocyte subsets.

#### 91 **Results**

# 92 The T cell compartment distinguishes critical SARS-CoV-2 infection from other disease 93 states.

94 To obtain a global view of the T cell response within and between disease states, peripheral blood 95 mononuclear cells (PBMCs) were isolated from the blood of patients and spectral cytometry was 96 performed using a T cell-centric antibody panel. Initially, T cell populations were manually gated 97 (Figure s1) and differences in the proportion of each population between patients were identified by 98 an unsupervised Principal Component Analysis (PCA), where each data point represents one patient 99 sample (Figure 1a). When the COVID-19 severity of each patient was superimposed onto the PCA 100 patients with critical infection separated distinctly across the first component (dim 1, accounted for 101 31.8% of the variance) from most other patient samples (Figure 1a). Visualisation of the 102 contribution of each T cell population proportion to the principal components revealed that the 103 expression of activation/proliferation markers HLA-DR, Granzyme B (GZMB), Perforin (PFN), 104 and Ki-67 on central memory ( $T_{CM}$ ), effector memory ( $T_{EM}$ ), and effector memory re-expressing 105 CD45RA ( $T_{EMRA}$ ) contribute to the separation of samples in dimension 1 (Figure 1b). Furthermore, the proportions of these activated, memory  $CD4^+$  and  $CD8^+$  T cell subsets were negatively 106 107 correlated to those of CD4<sup>+</sup> and CD8<sup>+</sup> naïve T cells ( $T_N$ ) (Figure 1b).

108

# 109 Metaclusters of cytotoxic CD4<sup>+</sup> T cells differentiate critical and severe SARS-CoV-2 infection

To determine which T cell populations may be implicated in progression from severe to critical COVID-19, patients in those groups were selected for further analysis. To fully capture the heterogeneity of activation and cytotoxic marker expression in the T cell compartment of these patients, unbiased clustering was performed. FlowSOM clustering was set to create 25 metaclusters (Mcs) and fast interpolation-based t-SNE (Fit-SNE) was used to visualise the proportion of each Mc (Figure 2a & b), with a heatmap generated for phenotyping (Figure 2c). As the T-cell panel included markers to define conventional CD4<sup>+</sup> and CD8<sup>+</sup> subsets, CD4<sup>-</sup>CD8<sup>-</sup> Mcs (7, 8, 11, 14 and

117 22) were excluded and a Partial Least Squares Discriminant Analysis (PLS-DA) was performed to 118 identify the Mcs that contribute to variance between severe and critical infection. Like the PCA 119 (Figure 1b) the PLS-DA revealed distinct separation of severe and critical patients, with 43.6% of 120 the variance in the proportion of Mcs accounted for in the first component (Figure 2d). Mc25, 15, 121 and 5 were enriched in critical infection, with Mc23 and 2 enriched in severe infection patients 122 (Figure 2e & b). To confirm that the difference in these Mcs were not an artefact of the 123 unsupervised nature of the PLS-DA, unpaired Mann-Whitney U-tests comparing the proportions of 124 each Mc between severe and critical patients was performed. Mc25 (GZMB<sup>+</sup>PFN<sup>+</sup> CD4<sup>+</sup> CD45RO<sup>-</sup>, 125 CCR7<sup>-</sup>), Mc15 (GZMB<sup>+</sup>PFN<sup>+</sup> CD4<sup>+</sup> CD45RO<sup>+</sup>, CCR7<sup>-</sup>), and Mc5 (HLA-DR<sup>+</sup> CD4<sup>+</sup> CD45RO<sup>+</sup>, 126 CCR7<sup>+</sup>) were significantly enriched in critical compared to severe infection (Figure 2f). While the 127 expression of CCR7 and CD45RO on Mc25 and 15 suggest a T<sub>EMRA</sub> and T<sub>EM</sub> phenotype 128 respectively, these Mcs also appeared to express intermediate levels of CXCR5 on the heatmap, a 129 feature of CD4<sup>+</sup> T<sub>FH</sub> cells (Figure 2c). However, Mcs 25 and 15 displayed a spectrum of expression 130 of CXCR5 (Figure s2) and thus this analysis did not allow definitive determination of  $T_{FH}$ 131 phenotype. Therefore, Mc25 and 15 represent cytotoxic CD4<sup>+</sup> T lymphocyte subsets, with Mc5 132 being a population of activated  $T_{CM}$  cells. The proportion of Mc23 (CD8<sup>+</sup> CD45RO<sup>-</sup>, CCR7<sup>+</sup>) and 133 Mc2 (CD4<sup>+</sup> CD45RO<sup>-</sup>, CCR7<sup>+</sup>) were significantly greater in severe patients than critical, 134 representing non-activated naïve  $(T_N)$  CD8<sup>+</sup> and CD4<sup>+</sup> T cells, respectively (Figure 2f). This 135 analysis suggests an expansion of activated and cytotoxic CD4<sup>+</sup>T cells populations and a decrease 136 in the proportion of  $T_N$  cell subsets is involved in progression from severe to critical SARS-CoV-2 137 infection.

138

## 139 Cytotoxic CD4<sup>+</sup> T lymphocytes are characteristic of disease progression

As the proportions of naïve and memory T cells were negatively correlated (Figure 1c), the distribution of naïve/memory subsets were further explored in the  $CD4^+$  non- $T_{FH}$  and  $CD8^+$  T cell compartments by manual gating on CD45RO and CCR7 (Figure 3a). Critical patients exhibited

143 increased proportions of  $CD8^+$  T<sub>EMRA</sub> cells and a reduction in the proportion of  $CD4^+$  T<sub>N</sub> cells, 144 compared to both mild and severe disease (Figure 3b). In contrast, the T cell compartments in 145 asymptomatic, mild, moderate, and severe patients were composed of comparable proportions of  $T_N$  $CD4^+$  and  $CD8^+$  cells. While the proportion of  $CD4^+$  T<sub>EMRA</sub> cells was not significantly elevated, 146 147 critical patients had increased expression of the activation marker HLA-DR on CD4<sup>+</sup> T<sub>EMRA</sub> cells 148 compared to those with asymptomatic or mild disease (Figure 3c). There was also a notable increase 149 in the proportion of  $CD8^+$  T<sub>EMRA</sub> cells expressing the activation marker PD-1 as disease severity 150 worsened (Figure 3c). As Mc25 and 15 could not clearly be defined as T<sub>FH</sub> cell populations, manually gated CXCR5<sup>hi</sup> CD4<sup>+</sup> T<sub>FH</sub> cells were selected for further analysis. While the proportion of 151 152 total T<sub>FH</sub> and CCR7<sup>+</sup>PD-1<sup>-</sup> T<sub>FH</sub> cells was not significantly different between groups, the proportion 153 of circulating PD-1<sup>+</sup>CCR7<sup>-</sup>  $T_{FH}$  cells (cT<sub>FH</sub>) was elevated in critical infection (Figure 3d).

154

155 The computational analyses in Figures 1 and 2 revealed distinct populations of cytotoxic 156 (GZMB<sup>+</sup>PFN<sup>+</sup>) CD4<sup>+</sup> T cell subsets enriched in critical disease. As cytotoxic CD8<sup>+</sup> T cells have been correlated with disease severity and mortality in COVID-19,<sup>22</sup> the proportion of GZMB<sup>+</sup>PFN<sup>+</sup> 157 CD4<sup>+</sup> and CD8<sup>+</sup> subsets were of interest to investigate further. As a proportion of lymphocytes, 158 159 critical patients had expanded populations of cytotoxic CD4<sup>+</sup>, but not CD8<sup>+</sup> T cells. Cytotoxic CD4<sup>+</sup> 160 T cells made up a mean of 3.68% of the lymphocyte compartment in critical infection patients, and 161 between 0.41-1.28% in all other disease states (Figure 4a). To delineate the subsets of cytotoxic CD4<sup>+</sup> T cells contributing to this, the proportions of GZMB<sup>+</sup>PFN<sup>+</sup> T<sub>FH</sub> and CD4<sup>+</sup> non-T<sub>FH</sub> cells were 162 163 compared across disease states. Both these subsets were significantly elevated in critical disease, 164 and as such the phenotype of subpopulations within these subsets were explored further (Figure 4b). 165 Of the CD4<sup>+</sup> non-T<sub>FH</sub> cell compartment, there was a higher proportion of CD4<sup>+</sup> T<sub>EMRA</sub> cells 166 expressing GZMB<sup>+</sup>PFN<sup>+</sup> cells in critical infection (Figure 4c). This was in line with the 167 predominant T<sub>EM</sub> and T<sub>EMRA</sub> phenotype of cytotoxic compared to total CD4<sup>+</sup> non-T<sub>FH</sub> cells, which 168 were largely of a  $T_N$  and  $T_{CM}$  phenotype (Figure 4d). Similarly, cytotoxic CD4<sup>+</sup>  $T_{FH}$  cells were

- almost exclusively of a CCR7PD-1<sup>+</sup>  $cT_{FH}$  phenotype and total  $T_{FH}$  cells were predominantly of a
- 170 CCR7<sup>+</sup>PD-1<sup>-</sup> phenotype (Figure 4e). Finally, the proportion of cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T cells
- 171 was correlated to determine whether  $CD4^+$  cytotoxicity may be a compensating for  $CD8^+$  T cell
- 172 exhaustion. However, these two populations correlated positively with each other (p = 0.0039:
- 173 Figure 4f). From these data it appears that the expansion of cytotoxic  $CD4^+$   $cT_{FH}$  and  $T_{EMRA}$
- 174 populations during SARS-CoV-2 infection is unique to critical disease.
- 175

## 176 Discussion

177 Characterising immune responses that associate with different disease severities of COVID-19 may 178 help to define protective immune responses to SARS-CoV-2 and guide the rational development of 179 next-generation vaccines. This study provides a phenotypic analysis of the T cell response in 180 patients experiencing asymptomatic to critical SARS-CoV-2 infection. We confirm that the T cell 181 compartment is distinctly altered in critical SARS-CoV-2 infection, defined by an expansion of 182 effector memory subsets, and increased expression of activation and cytotoxic functional markers 183 on CD4<sup>+</sup> T cells. These data suggest a potentially pathogenic role of cytotoxic CD4<sup>+</sup> CTLs in the 184 progression of COVID-19.

185

186 CD4<sup>+</sup> T cells are well-established critical responders in viral infection; however, CTL function is 187 more commonly associated with CD8<sup>+</sup> T cell populations. As such, it is of interest that the top Mcs 188 associated with the progression of disease from severe to critical were activated and cytotoxic CD4<sup>+</sup> 189 T cell populations (Figure 2).  $CD4^+$  T cells can mediate host-cell death through secretion of granzyme B and perforin<sup>24,25</sup>, and CD4<sup>+</sup> CTLs have been identified during viral infections including 190 191 human immunodeficiency virus (HIV), human cytomegalovirus (CMV), Epstein Barr virus (EBV), influenza, dengue virus and more recently SARS-CoV-2.<sup>26</sup> In patients with COVID-19, CD4<sup>+</sup> T 192 193 cells expressing high levels of *PFN1*, *GZMB* and *GZMH* transcripts have been identified previously by scRNA-seq to be enriched in hospitalised compared to non-hospitalised COVID-19 patients.<sup>27</sup> 194 195 The data provided in this current study describes an increase in CD4<sup>+</sup> CTLs, and a unique expansion of GZMB<sup>+</sup>PFN<sup>+</sup> CD4 T<sub>EMRA</sub> cells during critical infection at the level of protein 196 197 expression. While the circulating T cell populations have been analysed in this cohort, high 198 infiltration of CD4<sup>+</sup> CTLs, as well as CD8<sup>+</sup> CTLs, have also been reported in the lung parenchyma of severely ill COVID-19 patients.<sup>24,28</sup> The elevated expression of HLA-II in the respiratory 199 200 epithelium provides a potential mechanistic basis for the role of CD4<sup>+</sup> CTLs in the profound host tissue damage associated with SARS-CoV-2 acute respiratory distress syndrome (ARDS).<sup>24</sup> 201

202

203 In the CD4 T<sub>FH</sub> cell compartment, critical patients also exhibited increased proportions of cytotoxic 204 cells, which were predominantly of a CCR7<sup>-</sup>PD-1<sup>+</sup> phenotype; such cells have been previously described as circulating T<sub>FH</sub> (cT<sub>FH</sub>) cells.<sup>29</sup> Cytotoxic T<sub>FH</sub> cells have been shown to induce B cell 205 death and to correlate negatively with antibody titres in recurrent Strep A infection in children.<sup>30</sup> 206 207 Post-mortem investigations have shown loss of germinal centre (GC) B cells and absence of GCs in the lymph nodes of COVID-19 decedents.<sup>31</sup> However, while cytotoxic cT<sub>FH</sub> cells were elevated and 208 209 correlated negatively to anti-S1/S2 SARS-CoV-2 antibodies in hospitalised patients, this correlation was not seen in non-hospitalised patients.<sup>27</sup> Conversely, antibody-secreting plasmablasts have been 210 correlated with mortality in COVID-19,<sup>22</sup> and higher antibody responses are associated with more 211 severe disease.<sup>32</sup> As there are limited studies investigating cytotoxic  $cT_{FH}$  in COVID-19, the 212 213 implications of cytotoxicity in cT<sub>FH</sub> cells require further investigation to assess any potential 214 detrimental effect this cell type may have on antibody responses to SARS-CoV-2.

215

CD4<sup>+</sup> T cell cytotoxicity has been proposed to be a compensatory mechanism to combat exhaustion 216 of CD8<sup>+</sup> T cells, in which CD8<sup>+</sup> CTL expression of GZMB and PFN decrease, and PD-1 217 increases.<sup>33,34</sup> In contrast, no change in the proportion of CD8<sup>+</sup> GZMB<sup>+</sup>PFN<sup>+</sup> subsets was observed 218 219 here across disease severities. Moreover, PD-1 expression was not highlighted as a key variable in the separation of disease states in the PCA. This suggests that if CD8<sup>+</sup> CTL exhaustion was present 220 221 it was not a differentiating feature of disease progression. As such, the increased proportion of PD-1<sup>+</sup>CD8<sup>+</sup> T<sub>EMRA</sub> cells in critical infection likely represents a phenotype of increased activation, rather 222 223 than functional exhaustion. In line with this view, previous studies have reported elevated 224 frequencies of hyperactivated CD8<sup>+</sup> cells, defined by expression of HLA-DR<sup>+</sup>CD38<sup>+</sup>PD-1<sup>+</sup>TIM-3<sup>+</sup>, in severe and critical SARS-CoV-2 infection.<sup>21,22</sup> While no difference in cytotoxicity was reported 225 226 here, GZMB and PFN expression has been correlated with critical disease and mortality in COVID-19.<sup>22,35-39</sup> Rha et al., (2021) reported GZMB and PFN were expressed by almost all SARS-CoV-2-227

specific multimer<sup>+</sup> CD8<sup>+</sup> T cells.<sup>40</sup> As such, enrichment for SARS-CoV-2 specific T cells may provide more insight into the changes in proportion and phenotype of cytotoxic CD8<sup>+</sup> T cells between disease states. In combination with these studies, the data presented here suggest that hyperactivated effector memory subsets of CD8<sup>+</sup> T cells may contribute to COVID-19 progression.

232

233 Investigating the immune response in asymptomatic and mild disease can shed light on the immune 234 response that effectively controls viral replication and disease progression. Control of viral load by T cells was demonstrated in B-cell depleted Rhesus Macaques<sup>41</sup>, and CD8<sup>+</sup> T cell responses 235 236 correlated with better clinical outcome in patients with inborn errors in humoral immune responses and B cell impairment in SARS-CoV-2 infection.<sup>42,43</sup> In the current study, asymptomatic and mild 237 238 patients exhibited low frequencies of activated or cytotoxic cells, and a predominantly naïve 239 phenotype in both the  $CD4^+$  and  $CD8^+$  compartments. However, there is an inherent limitation to 240 investigating the peripheral immune response in a respiratory infection where localised 241 inflammation and resident immune cell responses may not be reflected in circulation.<sup>44</sup> 242 Furthermore, this study did not investigate SARS-CoV-2-specific T cells, and as such a 243 proportionally smaller T cell response may be missed in these less severe disease states. It has been 244 shown previously that individuals with mild infection are less likely to have detectable SARS-CoV-2-specific T cell responses.<sup>45</sup> In combination with the relative lack of a robust T cell response in 245 246 asymptomatic and mild disease here, this may question the necessity of a strong T cell response to 247 prevent the progression of COVID-19. This is consistent with the diverse polyclonal, less 248 differentiated SARS-CoV-2 specific T cell response observed in children with mild and 249 asymptomatic T cell response than the clonally expanded memory T cell response with markers of 250 cytotoxicity and exhaustion present in adults.<sup>46</sup> The protective capacity of T cells should be 251 investigated further to assess whether preserved T cell response against variant SARS-CoV-2 viruses provide protection against severe disease, as has been suggested previously.<sup>12,13,16</sup> 252

254 Finally, there are several clinical variables that may confound this analysis, notably the impact of 255 age on the immune response to infection. The critical patients were older than asymptomatic and 256 mild patients which is reflective of the high median age of COVID-19 patients admitted to hospital 257 and ICU.<sup>47</sup> Age over 65 years is associated with a progressive decline in immune function 258 characterised by decreased thymic function, contraction of naive T cell populations, and perturbed T cell function, such as reduced cytokine production and proliferative capacity.<sup>48,49</sup> It has been 259 260 shown previously that SARS-CoV-2 immune dysregulation mimics that seen in age-related immunosenescence.<sup>50</sup> Without age-matched patients, the impact of age cannot be extricated from 261 262 that of disease severity on the T cell response to SARS-CoV-2.

263

The data presented in our study add to our understanding of the contribution of T cell responses to disease progression in SARS-CoV-2 infection. The distinct absence of a notable T cell response in asymptomatic disease but expansion of cytotoxic CD4<sup>+</sup> cT<sub>FH</sub> and T<sub>EMRA</sub> subset in critical disease, suggest that CTLs may be contributing to host tissue damage and systemic inflammatory disease. As such, the potentially detrimental role of T cell responses in COVID-19 should be considered in the development of next-generation therapies and vaccines against SARS-CoV-2.

## 270 Material and Methods

#### 271 Patient Demographics

272 SARS-CoV-2 PCR-positive patients and their household contacts were enrolled through the Royal 273 Prince Alfred (RPA) hospital COVID-19 clinic or virtual care system in March of 2020 (COVIMM 274 cohort). Ethics approval was granted by the RPA ethics committee, human ethics number X20-0117 275 and 2020/ETH00770. Verbal consent was given by all participants. Additional patients enrolled in 276 the COSIN study in June 2021 through seven hospital microbiology labs, and out-patient care units 277 across Sydney, Australia, as described by Balachandran et al. (2022) were also included. Ethics 278 approval was granted by Human Research Ethics Committees of the Northern Sydney Local Health 279 District and the University of New South Wales, NSW Australia (ETH00520), and written consent 280 was obtained from all patients.

281 SARS-CoV-2 infection was defined by a positive nasopharyngeal RT-PCR performed by accredited 282 laboratories within the Sydney Health District. Patients were classified as asymptomatic (n = 5), 283 mild (n = 18), moderate (n = 4), severe (n = 5), or critical (n = 3) (Supplementary Table 1). COVID-284 19 disease severity defined by the NIH as guidelines 285 (https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/). Patients were 286 classified as mild if their symptoms were self-manageable.

# 287 Immunophenotyping by spectral cytometry

Patient PBMCs were isolated from whole blood by Ficoll-density gradient separation, and cryopreserved in Heat-inactivated FBS with 10% DMSO at -80°c. Cryopreserved PMBC samples were thawed and diluted to a concentration of 1 x 10<sup>6</sup> live PMBCs in RMPI supplemented with 10% FCS and 100 ug/ml streptomycin and penicillin in a U-bottom 96-well plate. Cells were washed in FACS buffer, dead cells labelled with LIVE/DEAD<sup>TM</sup> Fixable Blue dye (Invitrogen) for 20 minutes at 4°C and washed twice in FACS buffer. Cells were stained with extracellular markers (Supplementary Table 2; CD3-BUV395 (1:20), CD4-PerCPCy5.5 (1:100), CD8-BUV496 (1:100),

295 CD19-BV510 (1:50), CD56-BV605 (1:50), HLA-DR-BV650 (1:50), CD45RO-BV786 (1:50), 296 CD197-PECy7 (1:20), and CXCR5-AF647 (1:20) in FACS buffer for 20 minutes at 4°C. Cells were 297 then permeabilised and fixed with Transcription Factor Buffer Set (BD Pharmingen<sup>TM</sup>) for 40 298 minutes at 4°C. Cells were washed then stained with intracellular markers (Supplementary Table 2) 299 PD-1-BV737 (1:50), Ki-67-BV711 (1:50), Perforin-PE (1:50), and Granzyme B-APC (1:20) in Transcription Factor wash buffer (BD Pharmingen<sup>TM</sup>). Anti-Mouse Ig, κ/Negative Control Particles 300 Set (BD<sup>TM</sup> CompBeads) were used for single stain controls and stained with corresponding 301 302 extracellular and intracellular stains. Fluorescent minus one (FMO) controls were included for 303 intracellular markers and stained at the concentration of patient samples at corresponding staining 304 times. The samples underwent a second fixation step with 4% paraformaldehyde for 30 minutes, 305 washed, and resuspended in 200 ml FACS buffer for acquisition. Patient samples and controls were 306 acquired using the 5-laser Cytek Aurora® Spectral Cytometer. Spectral unmixing was performed 307 using the inbuilt SpectroFlo® software after acquisition of unstained and single-stained controls and 308 before patient sample acquisition.

## 309 Data Analysis

Data analysis was performed in FlowJo v10.8.1, R v4.2.1, and GraphPad Prism v9. Dead cells, doublets, and debris were excluded in FlowJo v10.8.1 by FSC-A, FSC-H, SCC-A, and LIVE/DEAD dye (Figure S1). NKT and B cells were excluded by CD3<sup>+</sup>CD56<sup>+</sup> and CD3<sup>-</sup>CD19<sup>+</sup> phenotype, respectively. Compensation for unmixing errors was performed in FlowJo v10.8.1. Irregularities in staining and acquisition between batches were controlled by matching gates on control samples and applying identical gate lineage and functional marker expression within each staining batch.

To control for the differences between staining batches, the Principal Component Analysis (Figure 1) was calculated using 38 overlapping  $CD3^+$  T cell populations that were manually gated in FlowJo v10.8.1.  $CD4^+$  and  $CD8^+$  T cells were first divided into  $T_N$  (CCR7<sup>+</sup>CD45RO<sup>-</sup>),  $T_{CM}$ 

320 (CCR7<sup>+</sup>CD45RO<sup>+</sup>),  $T_{EM}$  (CCR7<sup>-</sup>CD45RO<sup>+</sup>),  $T_{EMRA}$  (CCR7<sup>-</sup>CD45RO<sup>-</sup>) subsets. The frequency of 321 CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>N</sub>,  $T_{CM}$ ,  $T_{EM}$ , and  $T_{EMRA}$  subsets, and the cells expressing HLA-DR, PD-1, 322 GRZMB, PFN, and Ki-67 in the  $T_{CM}$ ,  $T_{EM}$ , and  $T_{EMRA}$  subsets were included to assess the 323 significance of T cell function on disease status (Figure S2). Each population was calculated as a 324 proportion of its respective CD4<sup>+</sup> or CD8<sup>+</sup> T cell compartment, and these frequencies were used for 325 PCA analysis in R v4.2.1 using the Spectre package.<sup>51</sup>

326 For the comparison between severe and critical infection, the R package Spectre was utilised for 327 computational analyses (https://www.ncbi.nlm.nih.gov/pubmed/33840138). CD3<sup>+</sup> T cells were 328 exported for each patient sample. FlowSOM clustering created 25 metaclusters. Fit-SNE dimensionality reduction<sup>52</sup> was run on subsampled data of 50,000 cells from severe and critical 329 330 groups to create a representative plot between disease states and a heatmap plot of cellular marker 331 expression on each metacluster was created using the pheatmap function. To identify contributions 332 to differences between severe and critical infection, a partial least squares discriminant analysis (PLS-DA) was done.<sup>53</sup> To validate the phenotype of metaclusters, an FCS file of marker expression 333 334 on each metacluster was created using the write files function in Spectre. This allowed for clear 335 analysis of marker expression for each metacluster in FlowJo v10.8. After exclusion of CD4<sup>-</sup>CD8<sup>-</sup> 336 FlowSOM metaclusters, PLS-DA was performed to identify the variability in proportion of 337 metaclusters between severe and critical disease. Validation of the statistical differences in 338 proportion of metaclusters between groups was performed in GraphPrism v9.

The difference between groups were analysed by two-sided paired Mann-Whitney U-test, and nonparametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original False Discovery Rate (FDR) method of Benjamini and Hochberg. Statistical significance between groups in computational analyses were calculated with a permutation ANOVA, with correction for multiple comparisons by FDR method. Statistical significance was set as  $p \le 0.05$ .

# 345 Data availability

- The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
- 348

## 349 Acknowledgments

- 350 This work was supported by MRFF COVID-19 Vaccine Candidate Research Grant 2007221
- 351 (J.A.T., C.C., M.S., A.L.F.). F.M. □ W. and T.M.A. are supported by the International Society for
- 352 the Advancement of Cytometry (ISAC) Marylou Ingram Scholars program. COSIN cohort was
- 353 supported by Snow Medical Foundation as an investigator-initiated study. We acknowledge the
- support of the University of Sydney Advanced Cytometry Facility. The authors thank the study
- 355 participants for their contribution to this research and the clinical staff who collected the samples.

- 357
- 358
- 359
- 360

#### 361 References

- 362 1. WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. 2022.
- 263 2. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
- antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
- 365 infection. Nat Med. 2021; **27**: 1205–1211.
- 366 3. Cromer D, Steain M, Reynaldi A, Schlub TE, Sasson SC, Kent SJ, et al. Neutralising
  antibodies predict protection from severe COVID-19. Nat Comms. 2023 In Press.
- Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced
   neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021; 184:
   4220-4236.e13.
- Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, van Eeckhoudt S, et al. Antibody titres
  decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021; 10: 14951498.
- Vanshylla K, di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, et al.
   Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in
   humans. Cell Host Microbe. 2021: 29: 917-929.e4.
- 377 7. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, le Bert N, et al. Dynamics of SARS-CoV-
- 2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet
  Microbe. 2021; 2: 240-249
- 380 8. Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. Durability of mRNA-
- 1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science (1979). 2021; 373:
   1372-1377.
- 383 9. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. SARS-
- 384 CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19
- convalescent donors and vaccinees. Sci Immunol. 2021; 6: 782-787.

- 386 10. Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, et al. SARS-CoV-2-specific T cell
- memory is sustained in COVID-19 convalescent patients for 10 months with successful
   development of stem cell-like memory T cells. Nat Commun. 2021; 12.
- 11. Lu Z, Laing ED, Pena DaMata J, Pohida K, Tso MS, Samuels EC, et al. Durability of SARS-
- 390 CoV-2–Specific T-Cell Responses at 12 Months Postinfection. J Infect Dis. 2021; 224: 2010–
- 391 9.
- Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination
  induces immunological T cell memory able to cross-recognize variants from Alpha to
  Omicron. Cell. 2022; 185: 847-859.e11.
- 395 13. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2
- variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.
  Cell Rep Med. 2021; 2: 100355.
- Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad
   CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. Journal of
- 400 Clinical Investigation. 2021; **131**: e149335
- 401 15. Boni C, Cavazzini D, Bolchi A, Rossi M, Vecchi A, Tiezzi C, et al. Degenerate CD8 Epitopes
- Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out
  From the SARS-CoV-2 Variants Storm. Front Immunol. 2021; 12: 730051.
- 16. Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, et al. Structure-guided
  T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021; 184: 4401406 4413.e10.
- 407 17. Kent SJ, Khoury DS, Reynaldi A, Juno JA, Wheatley AK, Stadler E, et al. Disentangling the
- 408 relative importance of T cell responses in COVID-19: leading actors or supporting cast? Nat
- 409 Rev Immunol. 2022; **28**: 387-397.

- 410 18. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations
  with Age and Disease Severity. Cell. 2020; 183: 996-1012.e19.
- 413 19. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive features of
- 414 SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep. 2021; **36**:
- 415 109414.
- 416 20. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory
- T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat
  Commun. 2022; 13: 80.
- 419 21. Laing AG, Lorenc A, del Molino del Barrio I, Das A, Fish M, Monin L, et al. A dynamic
- 420 COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020; 26:
  421 1623–35.
- 422 22. Kuchroo M, Huang J, Wong P, Grenier JC, Shung D, Tong A, et al. Multiscale PHATE
  423 identifies multimodal signatures of COVID-19. Nat Biotechnol. 2022; 40: 681-691.
- 424 23. Bergantini L, d'Alessandro M, Cameli P, Cavallaro D, Gangi S, Cekorja B, et al. NK and T
- 425 Cell Immunological Signatures in Hospitalized Patients with COVID-19. Cells. 2021; 10:
  426 3182.
- 427 24. Kaneko N, Boucau J, Kuo HH, Perugino C, Mahajan VS, Farmer JR, et al. Temporal changes
  428 in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19.
- 429 Clinical Immunology. 2022; **237**: 108991.
- 430 25. Shenoy AT, Lyon De Ana C, Arafa EI, Salwig I, Barker KA, Korkmaz FT, et al. Antigen
  431 presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier
  432 immunity. Nat Commun. 2021; 12: 5834.
- 433 26. Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CML. Cytotoxic CD4 T
  434 Cells—Friend or Foe during Viral Infection? Front Immunol. 2017; 8: 19.

- 435 27. Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Imbalance
- 436 of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell. 2020;
- **183**: 1340-1353.e16.
- 438 28. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-
- 439 mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive
- 440 study. Lancet Infect Dis. 2020; **20**: 1135–40.
- 441 29. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating Precursor
  442 CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody
  443 Responses upon Antigen Reexposure. Immunity. 2013; **39**: 770–81.
- 444 30. Dan JM, Havenar-Daughton C, Kendric K, Al-kolla R, Kaushik K, Rosales SL, et al.
- 445 Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving
  446 antibody deficiency and aberrant TFH cells. Sci Transl Med. 2019; 11: 3776.
- Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss of
  Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell. 2020;
  183: 143-157.e13.
- 450 32. Sun J, Tang X, Bai R, Liang C, Zeng L, Lin H, et al. The kinetics of viral load and antibodies
  451 to SARS-CoV-2. Clinical Microbiology and Infection. 2020; 28: 1690.e1-1690.e4.
- 452 33. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion
  453 of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;
- **4**54 **11**: 827.
- 455 34. Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4+ T Cells, Their Differentiation
  456 and Function. Front Immunol. 2017; 8: 194.
- 457 35. Koutsakos M, Rowntree LC, Hensen L, Chua BY, van de Sandt CE, Habel JR, et al.
  458 Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
- 459 Cell Rep Med. 2021; **2**: 100208.

- 460 36. Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, et al.
- 461 Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell.
  462 2022; 185: 493-512.e25.
- 463 37. Kang CK, Han GC, Kim M, Kim G, Shin HM, Song KH, et al. Aberrant hyperactivation of
- 464 cytotoxic T-cell as a potential determinant of COVID-19 severity. International Journal of
- 465 Infectious Diseases. 2020; **97**: 313–21.
- 466 38. Jiang Y, Wei X, Guan J, Qin S, Wang Z, Lu H, et al. COVID-19 pneumonia: CD8+ T and NK
- 467 cells are decreased in number but compensatory increased in cytotoxic potential. Clinical
  468 Immunology. 2020; 218: 108516.
- 469 39. Chen Q, Yu B, Yang Y, Huang J, Liang Y, Zhou J, et al. Immunological and inflammatory
- profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. Int
  Immunopharmacol. 2021; 97: 107685.
- 472 40. Rha MS, Jeong HW, Ko JH, Choi SJ, Seo IH, Lee JS, et al. PD-1-Expressing SARS-CoV-2-
- 473 Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19.
  474 Immunity. 2021; 54: 44-52.e3.
- 475 41. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates
  476 of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021; **590**: 630–634.
- 477 42. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate V v., Lang H, Lazarski CA, et
- 478 al. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody
  479 Deficiency. J Clin Immunol. 2021; 41: 1146–53.
- 43. Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells
  contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;
  482 27: 1280–9.
- 483 44. Wauters E, van Mol P, Garg AD, Jansen S, van Herck Y, Vanderbeke L, et al. Discriminating
  484 mild from critical COVID-19 by innate and adaptive immune single-cell profiling of
  485 bronchoalveolar lavages. Cell Res. 2021; 31: 272–90.

- 486 45. Kroemer M, Spehner L, Vettoretti L, Bouard A, Eberst G, Pili Floury S, et al. COVID-19
- 487 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.
- 488 Journal of Infection. 2021; **82**: 282–327.
- 489 46. Khoo WH, Jackson K, Phetsouphanh C, Zaunders JJ, Alquicira-Hernandez J, Yazar S, et al.
- 490 Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with
- 491 mild/asymptomatic COVID-19. Clinical Immunology. 2023; **246**: 109209.
- 492 47. Gao Y, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe
  493 and critically ill COVID□19 patients: A review. Allergy. 2021; 76: 428–55.
- 494 48. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human
  495 vaccine immune responses. Immunity & Ageing. 2019; 16.
- 496 49. Jalali S, Harpur CM, Piers AT, Auladell M, Perriman L, Li S, et al. A high dimensional
  497 cytometry atlas of peripheral blood over the human life span. Immunol Cell Biol. 2022; 100:
  498 805–821.
- 499 50. Zheng Y, Liu X, Le W, Xie L, Li H, Wen W, et al. A human circulating immune cell
  500 landscape in aging and COVID-19. Protein Cell. 2020; 11: 740-770.
- 501 51. Ashhurst TM, Marsh Wakefield F, Putri GH, Spiteri AG, Shinko D, Read MN, et al.
- Integration, exploration, and analysis of high □ dimensional single □ cell cytometry data using
  Spectre. Cytometry Part A. 2022; 101: 237–53.
- 504 52. Linderman GC, Rachh M, Hoskins JG, Steinerberger S, Kluger Y. Fast interpolation-based t505 SNE for improved visualization of single-cell RNA-seq data. Nat Methods. 2019; 16: 243–
  506 245.
- 507 53. Marsh □ Wakefield F, Juillard P, Ashhurst TM, Juillard A, Shinko D, Putri GH, et al.
  508 Peripheral B □ cell dysregulation is associated with relapse after long □ term quiescence in
  509 patients with multiple sclerosis. Immunol Cell Biol. 2022; 100: 453–467.
- 510
- 511

#### 512 Figure Legends

513 Figure 1. Variance in the T cell compartment explained by COVID-19 severity. A) Principal 514 component analysis based on the relative abundance of 38 T cell populations in patients with 515 asymptomatic to critical COVID-19 (n = 35). Patient disease severity overlay on principal 516 component analysis where non-overlapping disease states represent a difference in the relative 517 abundance of T cell populations between groups. B) Variable contribution plot visualising the T cell 518 populations that contribute to the principal components. Arrow direction represents correlation, 519 where opposing direction is negative and adjacent arrows represent positive correlation between 520 variables. Differences between groups determined by FDR.

521

522 Figure 2. Unbiased clustering of T cell compartment in severe and critical patients. A) Flt-523 SNE visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n 524 = 5) and critical (n = 3) patient. B) FIt-SNE visualisation of alterations in proportion of metaclusters 525 making up the T cell compartment between severe and critical disease. C) Heatmap plot showing 526 the relative expression of each marker on self-organised map metaclusters. **D**) Partial Least Squares Discriminant Analysis of relative frequencies of 20 non-redundant CD4<sup>+</sup> and CD8<sup>+</sup> T cell 527 528 populations defined by automatic clustering. E) Christmas tree plot visualising the variables 529 contributing to variance between severe and critical disease as determined by PLS-DA F) Non-530 parametric Mann-Whitney U test of proportions of metaclusters between severe and critical 531 infection patients; error lines represent median  $\pm$  interquartile range.

532

Figure 3. Differentiation status of CD4<sup>+</sup> and CD8<sup>+</sup> T cell compartments. A) Summary bar plots representing frequency of CD4<sup>+</sup> and CD8<sup>+</sup> T cell naïve and memory subsets between disease states defined as  $T_N$  (CCR7<sup>+</sup>CD45RO<sup>-</sup>),  $T_{CM}$  (CCR7<sup>+</sup>CD45RO<sup>+</sup>),  $T_{EM}$  (CCR7<sup>-</sup>CD45RO<sup>+</sup>), and  $T_{EMRA}$ (CCR7<sup>-</sup>CD45RO<sup>-</sup>). B) Frequency of CD4<sup>+</sup> and CD8<sup>+</sup>  $T_N$  and  $T_{EMRA}$  subsets C) Frequency of CD4<sup>+</sup> and CD8<sup>+</sup>  $T_{EMRA}$  cells expressing HLA-DR and PD-1. D) Frequency of total  $T_{FH}$  cells defined by CXCR5<sup>hi</sup>CD4<sup>+</sup> phenotype, and CCR7<sup>+</sup>PD-1<sup>-</sup> and CCR7<sup>-</sup>PD-1<sup>+</sup> cT<sub>FH</sub> cells. Difference between

groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent median  $\pm$  interquartile range.

542

543 Figure 4. Cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T cells are expanded in critical infection. A) Frequency of 544  $GZMB^+PFN^+ CD4^+$  and  $CD8^+ T$  cells across disease states. **B**) Frequency of  $GZMB^+PFN^+$  non- $T_{FH}$ cells (CXCR5<sup>-/lo</sup>) and  $T_{FH}$  cells (CXCR5<sup>hi</sup>) as a proportion of all CD4<sup>+</sup> T cells C) Frequency of 545  $GZMB^+PFN^+$  CD4<sup>+</sup> T<sub>EMRA</sub> cells as a proportion of parent **D**) Summary bar plot representing the 546 547 differentiation status of total CD4<sup>+</sup> non-T<sub>FH</sub> cells and cytotoxic (GZMB<sup>+</sup>PFN<sup>+</sup>) CD4<sup>+</sup> T cells 548 defined as T<sub>N</sub> (CCR7<sup>+</sup>CD45RO<sup>-</sup>), T<sub>CM</sub> (CCR7<sup>+</sup>CD45RO<sup>+</sup>), T<sub>EM</sub> (CCR7<sup>-</sup>CD45RO<sup>+</sup>), and T<sub>EMRA</sub> 549  $(CCR7^{-}CD45RO^{-})$  in critical infection patients (n = 3). E) Summary bar plot representing the 550 differentiation status of total CD4<sup>+</sup> T<sub>FH</sub> (CXCR5<sup>+</sup>) cells and cytotoxic (GZMB<sup>+</sup>PFN<sup>+</sup>) CD4<sup>+</sup> T<sub>FH</sub> 551 cells by CCR7<sup>+</sup>PD-1<sup>-</sup> and CCR7<sup>-</sup>PD-1<sup>+</sup> (cT<sub>FH</sub>) cell phenotype in critical infection patients (n = 3). F) 552 XY plot of correlation between  $GZMB^+PFN^+ CD4^+$  and  $CD8^+ T$  cells as a proportion of total  $CD4^+$ 553 and CD8 T<sup>+</sup> cells, respectively. Difference between groups determined by non-parametric Kruskal-554 Wallis, with comparison of the rank mean of experimental groups by Original FDR method of 555 Benjamini and Hochberg; error bars represent median  $\pm$  interquartile range.



557

558 Figure 1. Variance in the T cell compartment explained by COVID-19 severity. A) Principal 559 component analysis based on the relative abundance of 38 T cell populations in patients with 560 asymptomatic to critical COVID-19 (n = 35). Patient disease severity overlay on principal 561 component analysis where non-overlapping disease states represent a difference in the relative 562 abundance of T cell populations between groups. B) Variable contribution plot visualising the T cell 563 populations that contribute to the principal components. Arrow direction represents correlation, where opposing direction is negative and adjacent arrows represent positive correlation between 564 565 variables. Differences between groups determined by FDR.



Figure 2. Unbiased clustering of T cell compartment in severe and critical patients. A) Flt-568 SNE visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n 569 = 5) and critical (n = 3) patient. B) FIt-SNE visualisation of alterations in proportion of metaclusters 570 571 making up the T cell compartment between severe and critical disease. C) Heatmap plot showing 572 the relative expression of each marker on self-organised map metaclusters. D) Partial Least Squares Discriminant Analysis of relative proportions of 20 non-redundant CD4<sup>+</sup> and CD8<sup>+</sup> T cell 573 populations defined by automatic clustering. E) Christmas tree plot visualising the variables 574 contributing to variance between severe and critical disease as determined by PLS-DA F) Non-575 576 parametric Mann-Whitney U test of proportions of metaclusters between severe and critical 577 infection patients; error lines represent median  $\pm$  interquartile range. 578



579

Figure 3. Differentiation status of CD4<sup>+</sup> and CD8<sup>+</sup> T cell compartments. A) Summary bar plots 580 581 representing frequency of CD4<sup>+</sup> and CD8<sup>+</sup> T cell naïve and memory subsets between disease states 582 defined as T<sub>N</sub> (CCR7<sup>+</sup>CD45RO<sup>-</sup>), T<sub>CM</sub> (CCR7<sup>+</sup>CD45RO<sup>+</sup>), T<sub>EM</sub> (CCR7<sup>-</sup>CD45RO<sup>+</sup>), and T<sub>EMRA</sub> (CCR7<sup>-</sup>CD45RO<sup>-</sup>). **B**) Frequency of CD4<sup>+</sup> and CD8<sup>+</sup>  $T_N$  and  $T_{EMRA}$  subsets **C**) Frequency of CD4<sup>+</sup> 583 584 and CD8<sup>+</sup> T<sub>EMRA</sub> cells expressing HLA-DR and PD-1. D) Frequency of total T<sub>FH</sub> cells defined by CXCR5<sup>hi</sup>CD4<sup>+</sup> phenotype, and CCR7<sup>+</sup>PD-1<sup>-</sup> and CCR7<sup>-</sup>PD-1<sup>+</sup> cT<sub>FH</sub> cells. Difference between 585 586 groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of 587 experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent 588 median  $\pm$  interquartile range.



591 Figure 4. Cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T cells are expanded in critical infection. A) Frequency of GZMB<sup>+</sup>PFN<sup>+</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells across disease states. B) Frequency of GZMB<sup>+</sup>PFN<sup>+</sup> non-T<sub>FH</sub> 592 cells (CXCR5<sup>-/lo</sup>) and T<sub>FH</sub> cells (CXCR5<sup>hi</sup>) as a proportion of all CD4<sup>+</sup> T cells C) Frequency of 593 GZMB<sup>+</sup>PFN<sup>+</sup> CD4<sup>+</sup> T<sub>EMRA</sub> cells as a proportion of parent D) Summary bar plot representing the 594 differentiation status of total CD4<sup>+</sup> non-T<sub>FH</sub> cells and cytotoxic (GZMB<sup>+</sup>PFN<sup>+</sup>) CD4<sup>+</sup> T cells 595 defined as T<sub>N</sub> (CCR7<sup>+</sup>CD45RO<sup>-</sup>), T<sub>CM</sub> (CCR7<sup>+</sup>CD45RO<sup>+</sup>), T<sub>EM</sub> (CCR7<sup>-</sup>CD45RO<sup>+</sup>), and T<sub>EMRA</sub> 596  $(CCR7^{-}CD45RO^{-})$  in critical infection patients (n = 3). E) Summary bar plot representing the 597 598 differentiation status of total CD4<sup>+</sup> T<sub>FH</sub> (CXCR5<sup>+</sup>) cells and cytotoxic (GZMB<sup>+</sup>PFN<sup>+</sup>) CD4<sup>+</sup> T<sub>FH</sub> cells by CCR7<sup>+</sup>PD-1<sup>-</sup> and CCR7<sup>-</sup>PD-1<sup>+</sup> (cT<sub>FH</sub>) cell phenotype in critical infection patients (n = 3). F) 599 600 Pearson correlation between GZMB<sup>+</sup>PFN<sup>+</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells as a proportion of total CD4<sup>+</sup> 601 and CD8 T<sup>+</sup> cells, respectively. Difference between groups determined by non-parametric Kruskal-602 Wallis, with comparison of the rank mean of experimental groups by Original FDR method of 603 Benjamini and Hochberg; error bars represent median  $\pm$  interguartile range. 604





606 Supplementary Figure 1. Gating strategy for T cells subsets. Human peripheral blood 607 mononuclear cells (PBMCs) were analysed by spectral cytometry. A) Dead cells, cell aggregates, 608 and myeloid cells were excluded by LIVE/DEAD, time, FSC-H, FSC-A, and SSC-A. T cells were isolated by CD3<sup>+</sup>CD19<sup>-</sup> and CD3<sup>+</sup>CD56<sup>-</sup> phenotype to exclude B cells and NKT cells, respectively. 609 **B**) T cells were divided into  $CD4^+$  and  $CD8^+$  T cells.  $CD4^+$  T cells were divided further into 610  $CXCR5^{-/lo} CD4^+$  non- $T_{FH}$  cells and  $CXCR5^{hi} T_{FH}$  cells.  $T_{FH}$  cells were defined as  $cT_{FH}$  by  $CCR7^-$  PD-1<sup>+</sup> and as  $CCR7^+$ PD-1<sup>-</sup> cells.  $CD4^+$  non- $T_{FH}$  and  $CD8^+$  T cells were divided into naïve/memory 611 612 subsets defined as T<sub>N</sub> (CCR7<sup>+</sup>CD45RO<sup>-</sup>), T<sub>CM</sub> (CCR7<sup>+</sup>CD45RO<sup>+</sup>), T<sub>EM</sub> (CCR7<sup>-</sup>CD45RO<sup>+</sup>), and 613 614 T<sub>EMRA</sub> (CCR7<sup>-</sup>CD45RO<sup>-</sup>). Flow plots of representative non-infected control sample COVIMM\_093 and performed in FlowJo v10.8.1. 615

616



Supplementary Figure 2. Expression of lineage and functional markers on FIt-SNE of
 metaclusters. Relative expression of cellular marker expression on FIt-SNE visualisation of
 FlowSOM automatic clustering of a subsample of T cells from each severe (n = 5) and critical (n =
 3) patient.

Peak disease status (n)	Median age (range)	Days post positive swab (range)
Asymptomatic (5)	30 (25-51)	11 (5-32)
Mild (18)	31 (12-60)	15 (5-49)
Moderate (4)	58 (55-79)	21 (14-28)
Severe (5)	49 (24-69)	14 (14-112)
critical (3)	65 (59-65)	28 (28)
Total	35 (12-79)	14 (5-12)

# 624 Supplementary Table 1. Patient clinical characteristics

Product	Fluorophore	Clone	Detector	Species raised in	Source
CD3	BUV395	SK7	UV375_C	Mouse	BD Horizon <sup>™</sup>
Invitrogen LIVE/DEAD <sup>TM</sup> Fixable Blue Dead Cell Stain Kit, for UV excitation	N/A	N/A	UV450	Mouse	Invitrogen
$CD8^{\dagger}$	BUV496	RPA-T8	UV514	Mouse	BD Horizon <sup>™</sup>
PD-1 <sup>†‡</sup>	BUV737	EH12.2	UV737_	Mouse	BD Horizon <sup>™</sup>
CD19	BV510	HIB19	V510_	Mouse	BioLegend®
CD56	BV605	NCAM16.2	V598	Mouse	BD Biosciences <sup>©</sup>
HLA-DR <sup>†‡</sup>	BV650	G46-6	V660_C	Mouse	BD Biosciences <sup>©</sup>
Ki-67 <sup>†‡</sup>	BV711	Ki67	V720	Mouse	BioLegend®
$CD45RO^{\dagger}$	BV786	UCHL1	V780_A	Mouse	BioLegend®
$CD4^{\dagger}$	PerCPCy5.5	RPA-T4	B695_A	Mouse	BioLegend®
Perforin <sup>†‡</sup>	PE	B-D48	YG582_D	Mouse	BioLegend®
CD197(CCR7) <sup>†</sup>	PECy7	G043H7	YG780_A	Mouse	BioLegend®
Granzyme B <sup>†‡</sup>	APC	QA16A02	R660_C	Mouse	BioLegend®
$CXCR5^{\dagger}$	AF647	RF8B2	R679	Rat	BD Biosciences <sup>©</sup>

626 Supplementary Table 2. Antibody Panel

627 <sup>†</sup>Markers used for automatic clustering; <sup>‡</sup> Intracellular markers